Clearwater Paper Corp. 10-Q Summary: Q1 2025
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Clearwater Paper Corp. is a manufacturer of bleached paperboard focused on independent converters in North America. The company sold its tissue (consumer products) operations in November 2024; results for this division are now reported as discontinued operations. The company operates as a single segment following the divestiture.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $378.2 million | $258.8 million |
| Gross Margin | $36.6 million (9.7%) | $33.3 million (12.9%) |
| Loss from Continuing Operations | $(5.9) million | $(2.1) million |
| Net Income (Loss) | $(6.3) million | $17.2 million |
| Adjusted EBITDA (Continuing Ops) | $29.8 million | $14.2 million |
| Operating Cash Flow | $1.5 million | $59.2 million |
| Cash and Equivalents (End of Period) | $44.0 million | $55.2 million |
| Total Debt | $282.2 million | Filing text does not provide a clear comparative total debt figure for Q1 2024 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 46% year-over-year, driven primarily by the inclusion of the Augusta, Georgia paperboard facility acquired in May 2024. Shipments increased 54.6%, though average sales price per ton decreased 7.5% due to market conditions.
- Profitability: While GAAP net income swung from a profit of $17.2 million in Q1 2024 to a loss of $6.3 million in Q1 2025, this is largely due to the exclusion of the profitable tissue division (discontinued operations) in the current period. Adjusted EBITDA from continuing operations improved significantly by 110% to $29.8 million.
- Cost Structure: Cost of sales rose 51% due to the Augusta acquisition. However, input costs per ton decreased due to deflation and the absence of weather-related expenses seen in Q1 2024.
- Cash Flow: Operating cash flow dropped to $1.5 million from $59.2 million, reflecting the removal of the tissue division's cash generation and lower operating performance in the remaining business.
Guidance, Outlook, and Risks
- Outlook: Management expects Q2 2025 sales volumes to be higher than Q1. Energy costs are expected to decrease seasonally, and fixed cost reduction efforts should yield further benefits. An annual maintenance outage at the Cypress Bend mill will increase maintenance expenses in Q2.
- Tariffs: The company is evaluating the impact of new U.S. tariffs announced in April 2025. While some raw materials from Canada are exempt under USMCA, the company does not currently expect a significant impact on fiscal 2025 results but notes uncertainty regarding potential retaliatory tariffs.
- Cost Reduction Plan: A plan announced in early 2025 aims to right-size operations post-tissue sale. The company expects total severance costs of $5 to $7 million by year-end; $4.4 million was incurred in Q1.
- Legal Proceedings: The company is a defendant in an environmental lawsuit in Georgia regarding PFAS contamination. Management believes it has meritorious defenses.
- Capital Allocation: The company repurchased $10.9 million of common stock in Q1 2025. Capital expenditures for 2025 are projected at $80 million to $90 million.
Investor Verification Checklist
- Verify the integration progress and financial performance of the Augusta, Georgia facility, which is driving volume growth but also integration costs ($3.8 million in Q1).
- Monitor the execution of the cost reduction plan and the remaining severance liability ($0.7 million as of March 31, 2025).
- Assess the impact of the new U.S. tariff regime on input costs, specifically for non-USMCA compliant materials.
- Review the status of the PFAS environmental litigation in Georgia for potential contingent liabilities.
- Track the company's ability to maintain compliance with credit agreement covenants given the reduced operating cash flow compared to the prior year.